Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregg Gilbert has reaffirmed a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and increased the price target from $31 to $37.
January 04, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Gregg Gilbert maintains a Buy rating on Collegium Pharmaceutical and raises the price target from $31 to $37.
The increase in price target by Truist Securities suggests a positive outlook on Collegium Pharmaceutical's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100